Consequences of stopping growth hormone (GH) therapy in young GH deficient patients with childhood onset disease.

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Patients with adult onset GH deficiency represent fully developed individuals who have various organic, cerebral defects.

By contrast, patients with childhood onset disease represent a heterogenous group comprising individuals with conditions, such as idiopathic isolated GH deficiency, genetic defects and organic defects.

Who Took Part

According to the abstract, 19 patients were involved.

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a placebo-controlled study.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

The subject headings attached to it are Age Factors, Age of Onset, Alkaline Phosphatase, Body Composition, Dwarfism, Pituitary, Glucose and Heart.

What This Means in Plain Language

The paper is a placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.